A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)
Clinical trial NCT03964233 · COMPLETED
Trial details
- NCT number
- NCT03964233
- Sponsor
- Boehringer Ingelheim
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-20
- Primary completion
- 2024-09-05
- Enrollment
- 119
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.